-
1
-
-
84888012165
-
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing
-
Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94(6):640-645.
-
(2013)
Clin Pharmacol Ther.
, vol.94
, Issue.6
, pp. 640-645
-
-
Caudle, K.E.1
Thorn, C.F.2
Klein, T.E.3
-
2
-
-
84901604087
-
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis
-
Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.JClin Oncol. 2014;32(10):1031-1039.
-
(2014)
JClin Oncol.
, vol.32
, Issue.10
, pp. 1031-1039
-
-
Rosmarin, D.1
Palles, C.2
Church, D.3
-
3
-
-
85010657688
-
DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: A secondary analysis of the PETACC-8 randomized clinical trial
-
published online January 21, 2016
-
Boige V, Vincent M, Alexandre P, et al. DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial [published online January 21, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2015.5392.
-
JAMA Oncol.
-
-
Boige, V.1
Vincent, M.2
Alexandre, P.3
-
4
-
-
84961288145
-
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)
-
Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12):dju298.
-
(2014)
J Natl Cancer Inst.
, vol.106
, Issue.12
-
-
Lee, A.M.1
Shi, Q.2
Pavey, E.3
-
5
-
-
84879413456
-
A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity
-
Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther. 2013;94(1):158-166.
-
(2013)
Clin Pharmacol Ther.
, vol.94
, Issue.1
, pp. 158-166
-
-
Offer, S.M.1
Lee, A.M.2
Mattison, L.K.3
Fossum, C.4
Wegner, N.J.5
Diasio, R.B.6
-
6
-
-
84875421741
-
Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity
-
Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 2013;73(6):1958-1968.
-
(2013)
Cancer Res.
, vol.73
, Issue.6
, pp. 1958-1968
-
-
Offer, S.M.1
Wegner, N.J.2
Fossum, C.3
Wang, K.4
Diasio, R.B.5
-
7
-
-
67349223302
-
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy
-
Kleibl Z, Fidlerova J, Kleiblova P, et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma. 2009;56(4):303-316.
-
(2009)
Neoplasma
, vol.56
, Issue.4
, pp. 303-316
-
-
Kleibl, Z.1
Fidlerova, J.2
Kleiblova, P.3
|
